Navigation Links
Trading in Regeneron Common Stock Halted
Date:6/17/2011

TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today.  The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (BLA) for EYLEA™, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  

Regeneron submitted a BLA for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the EYLEA BLA is August 20, 2011.

About EYLEAVascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

EYLEA (aflibercept ophthalmic solution), also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and highly potent blocker of these growth factors.  EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of the neovascular form of age-related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macu
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shenzhen Wuzhou Changlian International Trading Co. Establishes Relationship with Hospital in Africa
2. Shenzhen Wuzhou Changlian International Trading Co. Announces Arrival of New Infrared Thermometer Series
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Internal Fixation Systems, Inc. Announces Form S-1 Declared Effective by SEC and Anticipated Quotation for Trading on OTCQB
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. Trading Halted Today in Optimer Pharmaceuticals Stock
7. Milestone Scientific Inc. Commences Trading on the OTC Pink
8. ERT to Change Trading Symbol to "ERT" Effective March 7, 2011 to Properly Align Business Brand
9. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
10. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
11. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health ... community pharmacies as winners of its prestigious Independent Pharmacy ... Conference , one of the nation,s largest gatherings of ... winners – family-owned pharmacies from Ohio ... Texas – were selected for implementing exceptionally ...
(Date:7/25/2014)... 2014 According to a new ... China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern ... Trends and Forecast (Value and Volume), 2013 - 2019", ... billion in 2012 and is expected to grow at ... reach USD 32.24 billion in 2019. Browse ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... 20 Accuray, Inc., (Nasdaq: ARAY ), ... announced today that it ranked number 113 on ... fastest growing technology, media, telecommunications, life sciences and clean ... percentage of fiscal year revenue growth during the period ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) third quarter ... Wednesday, October 27, 2010 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2010 third quarter financial results and other ...
Cached Medicine Technology:Accuray Ranked Number 113 Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2Accuray Ranked Number 113 Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:7/25/2014)... According to a new market research report "Machine ... ultrasound emission, lubricating oil analysis, corrosion monitoring, motor ... Global Forecast to 2014 - 2020", published by ... to reach $2.50 at a CAGR of 7.16% ... data Tables and 57 Figures spread through 353 ...
(Date:7/25/2014)... As reported by the New Orleans Advocate ... (7/3), the state of Louisiana has recently seen a ... than cocaine. Officials believe the increase is due to a ... of marijuana. However, both doctors and police confirm that that ... to call it “poison,” doctors have acknowledged that the Louisiana ...
(Date:7/25/2014)... Society of America (GSA) the nation,s ... aging has chosen Heather M. Young, PhD, ... as the 2014 recipient of the Doris Schwartz ... presented by GSA,s Health Sciences Section, is given ... of outstanding and sustained contribution to gerontological nursing ...
(Date:7/25/2014)... As reported by People Magazine in the ... Shore and Getting Sober (7/15), one of the most ... spoken out to the public about his personal transformation. Now, ... Situation admits that moving on with his life was a ... other drugs in 2012 and even spent some time in ...
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
Breaking Medicine News(10 mins):Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... (HealthDay News) -- Obesity and insulin resistance constitute a greater ... to a new study that found drinking modest amounts of ... For their study, published online May 23 in ... to either abstain from alcohol or drink one (women) or ...
... Mathematical models analyzing how a cholera outbreak ... the most effective vaccination strategies for preventing future ... The mathematical models employed to analyze a ... that mass vaccinations deployed strategically could prevent future ...
... impairment is evident early on in preschool children with ... children. Age of onset of first seizure is a ... first to evaluate cognitive impairment in children age three ... , a journal published by Wiley-Blackwell on behalf of ...
... June 2, 2011 In a multicenter ... found that higher doses of stereotactic radiation therapy ... patients with low-to-intermediate-risk prostate cancer. Results of ... Clinical Oncology , showed that stereotactic body radiation ...
... WEDNESDAY, June 1 (HealthDay News) -- People who become very afraid ... attack also seem to have more inflammation, an indicator that they ... less fearful, a small British study suggests. The finding, published ... us of the connection between the mind and the body," said ...
... Clinical Cardiology reveals that in men with ... libido, erectile dysfunction, and sexual performance. Chronic heart failure ... fatigue and exercise intolerance. HF patients experience decreased libido ... of pacemaker that paces the right and left ventricle, ...
Cached Medicine News:Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2Health News:UF researchers suggest cholera vaccination strategies for Zimbabwe 2Health News:Cognitive impairment seen in preschool children with epilepsy 2Health News:Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer 2Health News:Fear of Dying During Heart Attack May Make Matters Worse 2Health News:Fear of Dying During Heart Attack May Make Matters Worse 3
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: